Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares were up 4.1% during trading on Monday . The company traded as high as GBX 4.40 ($0.06) and last traded at GBX 4.40 ($0.06). Approximately 1,792,901 shares traded hands during trading, an increase of 253% from the average daily volume of 508,240 shares. The stock had previously closed at GBX 4.23 ($0.05).
Roquefort Therapeutics Stock Down 5.7 %
The firm’s 50-day simple moving average is GBX 3.95 and its 200 day simple moving average is GBX 4.27. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The company has a market cap of £5.30 million, a P/E ratio of -420.00 and a beta of 0.05.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
See Also
- Five stocks we like better than Roquefort Therapeutics
- Best Aerospace Stocks Investing
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- 3 Monster Growth Stocks to Buy Now
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Ride Out The Recession With These Dividend Kings
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.